Bionomics Limited/fi 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Neuphoria Therapeutics Inc. announced a revenue distribution of AUD $1.416 million from its participation in the former Cancer Therapeutics Cooperative Research Centre (CTx CRC).
Neuphoria Therapeutics Inc. announced its CEO, Spyridon Spyros Papapetropoulos, will transition from full-time CEO to an interim consulting role, focusing on a strategic transaction.
Neuphoria Therapeutics Inc. announced it has regained compliance with Nasdaq's listing rules after successfully holding its annual general shareholder meeting on December 12, 2025.
Neuphoria Therapeutics Inc. announced the results of its Annual Meeting, where shareholders elected two Class I directors, ratified the auditor, and approved executive compensation on an advisory basis.
Neuphoria Therapeutics Inc. has adopted a limited-duration stockholder rights plan to protect against unwanted takeovers and allow its Board to evaluate strategic alternatives.
Neuphoria Therapeutics Inc. announced its BNC210 Phase 3 trial for social anxiety disorder did not meet its primary or secondary endpoints, leading to program discontinuation.
Neuphoria Therapeutics Inc. received a 180-day extension from Nasdaq to regain compliance with listing rules by holding its annual general meeting by December 29, 2025.
Neuphoria Therapeutics Inc. has received a deficiency notification from Nasdaq for failing to hold its annual stockholder meeting within the required timeframe, though the company states it has a plan to regain compliance.
Neuphoria Therapeutics reports progress in its clinical programs, including the Phase 3 AFFIRM-1 trial for BNC-210 in social anxiety disorder, and highlights a cash runway extending into Q3 2026.
Neuphoria Therapeutics has regained compliance with Nasdaq's minimum bid price rule after maintaining a share price of $1.00 or greater for 10 consecutive business days.
Bionomics Limited has completed its redomiciliation to the United States, becoming a wholly-owned subsidiary of Neuphoria Therapeutics Inc., with Neuphoria shares commencing trading on Nasdaq.
The Supreme Court of New South Wales has approved Bionomics' re-domiciliation to the U.S., with Neuphoria Therapeutics Inc. becoming the parent company.
Bionomics shareholders have approved the company's re-domiciliation to the United States, with Neuphoria Therapeutics Inc. becoming the ultimate parent company.
Bionomics Limited has entered into an agreement with H.C. Wainwright & Co., LLC for an at-the-market offering of American Depositary Shares (ADS) up to $2 million.
Bionomics Limited and Neuphoria Therapeutics Inc. have amended their scheme implementation agreement, adjusting the exchange ratio and setting a shareholder vote for December 12, 2024, to approve the re-domiciliation to the U.S.
Bionomics Limited reports the resignation of board member Aaron Weaver, effective October 9, 2024.
Bionomics Limited plans to re-domicile from Australia to the United States by establishing a new parent company, Neuphoria Therapeutics Inc., in Delaware, subject to shareholder and regulatory approvals.
Bionomics Limited received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing it at risk of delisting.